Moderna’s Covid Shot Raises Immune Response in Kids Under 6 (1)

March 23, 2022, 1:52 PM UTC

Moderna Inc. said its Covid-19 vaccine produced a strong immune response in children under age 6 in initial results from a large final-stage trial that showed modest effectiveness in reducing omicron infections.

Based on the positive results and the need for Covid shots for young children, Moderna will submit the data to regulators in the U.S. and overseas as soon as possible, according to a statement. The company also said it would also apply for U.S. clearance of its vaccine in 6- to 11-year-olds, after consultation with regulators.

The Biden administration has been frustrated in attempts to expedite Covid ...

Learn more about Bloomberg Law or Log In to keep reading:

See Breaking News in Context

Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.

Already a subscriber?

Log in to keep reading or access research tools and resources.